Background: Episodic ataxia (EA) is an ion channel disorder that manifests as paroxysmal attacks of imbalance and incoordination. Episodic ataxia type 2 (EA2) is characterized by prolonged episodes of ataxia with interictal nystagmus and is caused by mutations in CACNA1A. All mutations identified thus far (to our knowledge) are nonsense or missense point mutations.
Arch Neurol. 2008; 65(6) :817-820 E P I S O D I C A T A X I A T Y P E 2 (EA2) (OMIM 108500) is a rare autosomal dominant neurologic disorder characterized by attacks of ataxia lasting hours to days and interictal nystagmus. 1 These attacks can be triggered by fatigue or emotional stress and are usually responsive to acetazolamide treatment. Episodic ataxia type 2 is caused by mutations in CACNA1A.
2 CACNA1A encodes the Cav2.1 subunit, which is the pore-forming and voltage-sensing subunit of a neuronal P/Q voltage-activated calcium channel expressed throughout the central nervous system but most abundantly in the cerebellum. 3 Episodic ataxia type 2 has been shown to be associated with CACNA1A point mutations, most often with mutations leading to a premature stop codon and sometimes with missense mutations (OMIM 601011). 1, 4, 5 More than 40 different mutations have been reported, and 19 others have been identified in our laboratory (F.R., unpublished data, May 2007). However, in some typical families with EA2, no mutation is detected in CACNA1A, 5, 6 suggesting the existence of other types of mutations undetectable by exon sequencing or by denaturing high-performance liquid chromatography (DHPLC) screening or the existence of additional and unidentified EA2 genes. Herein, we describe a large CACNA1A deletion in a family with EA2.
METHODS

CLINICAL DATA
Four patients in this family (II-3, III-1, III-2, and III-3) were examined.
week. Precipitating factors included sudden noise and emotional stress. These paroxysmal ataxic episodes lasted for minutes to hours and were accompanied by pallor, blurred vision, and phonophotophobia, and their severity was increased by physical exertion. Clinical examination disclosed multidirectional nystagmus and cerebellar ataxia. Brain magnetic resonance (MR) imaging showed moderate cerebellar vermian atrophy. An interictal electroencephalogram demonstrated mild slowing of background activity.
Patient III-1
Patient III-1, born in 1977, was evaluated in 1999. Since adolescence, he had experienced ataxic episodes lasting for 2 to 6 hours, preventing his ability to stand. These episodes were sometimes associated with migrainous headache. Clinical examination revealed interictal horizontal nystagmus. Additional signs were noted, including short stature, hypertrophy of calves and leg muscles, and a degree of facial dysmorphism. All investigations, including brain MR imaging, electroencephalogram, and muscle biopsy specimen, were normal or negative.
Patient III-2
Patient III-2, born in 1972, was evaluated in 2000. She reported stereotyped episodes of ataxia lasting for 15 minutes to 3 hours. Her clinical examination findings were normal except for pes cavus. Cerebral MR imaging was normal.
Patient III-3
Patient III-3, born in 1965, was evaluated in 1997. She had the same symptoms as those reported by her mother (II-3). Clinical examination disclosed horizontal nystagmus and permanent invalidating ataxia.
The conditions of patients II-3, III-1, III-2, and III-3 were improved by acetazolamide treatment.
Patient I-1
Patient I-1, a 98-year-old woman, had experienced attacks of paroxystic dizziness associated with headaches. The frequency decreased after age 70 years, and she developed progressive ataxia.
Patient II-2
Patient II-2 declined clinical evaluation. According to his relatives, during 30 years he experienced attacks associated with headache, dizziness, and ataxia lasting up to 1 day. The frequency of the attacks decreased at about age 55 years and disappeared at age 60 years.
GENOTYPING
Blood samples were obtained from patients II-3, III-1, and III-2, and genomic DNA was extracted using standard protocols. All 3 patients underwent genotyping with 6 polymorphic markers spanning the CACNA1A locus; these included 2 intragenic markers (D19S1150 and exon 47 CAG repeat) and 4 telomeric markers (D19S221 and 3 dinucleotide repeats, including a GT repeat located 219 kilobase [kb] 
LONG-RANGE POLYMERASE CHAIN REACTION AND SEQUENCING
Long-range polymerase chain reaction (PCR) amplifications were performed (TripleMaster PCR System; Eppendorf International, Westbury, New York) using primers located in intron 30 and after the stop codon of CACNA1A. Sequencing was performed with a primer located in intron 31 using standard protocols (ABI 3130 DNA analyzer; Applied Biosystems, Norwalk, Connecticut). Primers are available on request from the author.
QUANTITATIVE MULTIPLEX PCR OF SHORT FLUORESCENT FRAGMENTS
The quantitative multiplex PCR of short fluorescent fragments (QMPSF) method is described in detail elsewhere. 7 Oligonucleotide primer pairs for amplification of short fluorescent fragments corresponding to CACNA1A exons were designed using commercially available software (Primer PREMIER 5 Software; PREMIER Biosoft International, Palo Alto, California). Two multiplex PCRs were set up to estimate the copy number of CACNA1A exons. The first one (QMPSF1) screened exons 2, 4, 11, 16, 21, 25, 30, 34, 39, and 45, and the second one (QMPSF2) screened exons 30, 31, 32, 34, and 35. An additional primer set that amplified a short sequence of exon 13 in the hydroxymethylbilane synthase gene (HMBS; OMIM 609806), uninvolved in EA2, was used as an internal control. Primer sequences are available on request from the author. All DNA samples were reextracted using a commercially available kit (QIAamp DNA Blood Mini Kit; Qiagen, Study City, California). Multiplex PCR was performed as previously described. 8 Control DNA was amplified simultaneously with patient DNA. Polymerase chain reaction products were separated by capillary electrophoresis using a DNA analyzer (ABI 3130; Applied Biosystems). Quantification of the area of peaks corresponding to the tested exons and to the internal HMBS control was determined using commercially available analysis software (GeneMapper version 4.0, Applied Biosystems). Data for each exon were expressed using the following ratio: (the area of the peak corresponding to a tested exon for the patient divided by the area of the peak corresponding to HMBS for the patient) to (the area of the peak corresponding to the same tested exon for the control DNA divided by the area of the peak corresponding to HMBS for the control DNA). A ratio close to 1 is obtained when 2 copies of the tested exon are present, and the ratio is close to 0.5 when only 1 copy is present (hemizygous DNA).
RESULTS
The family was first screened for linkage using 2 intragenic polymorphic markers located in intron 7 (D19S1150) and in exon 47 (polymorphic CAG repeat). Patient II-3 was homozygous at D19S1150, and patients III-1 and III-2 were heterozygous; the 3 patients shared a common allele. An apparent nonmendelian inheritance was observed for the CAG polymorphic marker, as patient III-2 did not inherit any allele from her affected mother (II-3), suggesting the existence of a null allele (Figure 1) . Patients II-3 and III-2 had no incompatible genotype with a panel of 9 polymorphic microsatellite markers (AmpFlSTR Profiler kit, Applied Biosystems), eliminating inaccurate maternity information or sampling error. Sequencing of the region, including the CAG repeat and the hybridization sites for primers, excluded polymorphisms. Ratios obtained by QMPSF1 analysis were close to 1 for exons 2, 4, 11, 16, 21, 25, and 30 and were close to 0.5 for exons 34, 39, and 45. These results were consistent with a deletion of the Cterminal exons of CACNA1A. The results of the second QMPSF analysis indicated that the 5Ј boundary was located within intron 31 ( Table 1 and Table 2 ).
The 3Ј boundary was refined using 4 microsatellite markers for which at least 1 of 3 patients was heterozygous ( Figure 1 and Figure 2) . To determine the size and breakpoints of the deletion, we performed a long-range PCR amplification using a set of primers located in intron 30 and after the stop codon of the gene. We amplified a 2557-base pair (bp) fragment. The sequencing of this PCR product revealed that the deletion size was 39 567 bp. The deletion removes 8078 bp of intron 31, exons 32 to 47, and 3071 bp after the stop codon (Figure 3) . Sequence analysis of the deletion boundaries suggests that this deletion arose through homologous recombination of Alu sequences. There were no known additional genes within the deleted fragment (University of California Santa Cruz Genome Browser). 
COMMENT
We describe a 39.5-kb deletion that removes the last 16 coding exons at the 3Ј end of CACNA1A in 3 patients of a family with an EA2 phenotype. The existence of this deletion is supported by a polymorphic marker genotyping approach and a QMPSF analysis.
The deleted allele is predicted to lead to a truncated protein or to an absence of the protein caused by messenger RNA instability. The consequence of this mutation is most likely identical to that of previously reported premature stop codons observed in families with EA2. 5 All CACNA1A mutations reported thus far (to our knowledge) in EA2 are point mutations, including nonsense, missense, and small deletions or insertions. However, in some typical patients with EA2, routine sequencing or DHPLC screening of all 47 exons is negative, suggesting chromosomal rearrangements or regulatory mutations involving CACNA1A or genetic heterogeneity. Herein, we showed that large deletions involving CACNA1A might occur in patients with EA2. This type of mutation has recently been reported in another channelopathy, severe myoclonic epilepsy of infancy due to mutations in SCN1A (OMIM 182389), a gene coding for a sodium channel. 9 The systematic screening of intragenic deletions by methods such as multiplex QMPSF or multiplex ligationdependent probe amplification will probably expand the spectrum of CACNA1A deletions in EA2. These findings should be extended to larger cohorts to estimate the frequency of these deletions and their possible recurrence. 
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